Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q3 FY24 results · Oct–Dec 2023
Tatva Chintan Pharma Chem reported revenue from operations of ₹84.21 crore (down 30.2% from Q3 FY23) and net profit of ₹3.46 crore (down 70.3% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 84.21 | 120.61 | −30.2% | 96.67 | −12.9% |
| Other income | 1.21 | 1.52 | −20.4% | 0.76 | +60.1% |
| Total income | 85.42 | 122.13 | −30.1% | 97.42 | −12.3% |
| Profit before tax | 5.24 | 14.22 | −63.1% | 11.21 | −53.2% |
| Net profit for the period | 3.46 | 11.62 | −70.3% | 7.78 | −55.6% |
| EPS, basic (₹) | 1.48 | 5.24 | −71.8% | 3.43 | −56.9% |
| Net margin (%) | 4.1 | 9.6 | 8.0 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 86.07 | 113.54 | −24.2% | 92.57 | −7.0% |
| Other income | 1.21 | 1.07 | +12.7% | 0.76 | +59.9% |
| Total income | 87.28 | 114.61 | −23.8% | 93.33 | −6.5% |
| Profit before tax | 6.56 | 13.15 | −50.1% | 11.71 | −43.9% |
| Net profit for the period | 4.65 | 10.56 | −55.9% | 8.20 | −43.3% |
| EPS, basic (₹) | 1.99 | 4.76 | −58.2% | 3.63 | −45.2% |
| Net margin (%) | 5.4 | 9.3 | 8.9 |
Consolidated
- Filed with BSE
- 24 Jan 2024, 12:40 IST
- Board meeting
- 20 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Jan 2024, 12:40 IST
- Board meeting
- 20 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE